Jefferies analyst Michael Yee upgraded Aligos Therapeutics (ALGS) to Buy from Hold with a price target of $3, up from $2.50. While 2022 was a challenging year, Aligos continues to work through its various pipeline assets, Yee tells investors in a research note. Most importantly, the stock is at a $40M market capitalization and a "promising" nonalcoholic steatohepatitis pill, says the analyst. He believes the asset was recently derisked by "very positive" Madrigal Pharmaceuticals (MDGL) Phase III fibrosis data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALGS:
- Aligos Therapeutics upgraded to Buy from Hold at Jefferies
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
- Aligos Therapeutics initiates dosing in ALG-125755 trial
- Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)